Peripheral-Blood Stem Cells Versus Bone Marrow from Unrelated Donors

Publication Type
Journal Article
Year of Publication
2012
Authors
Anasetti, C; Logan, B; Lee, S; Waller, E; Weisdorf, D; Wingard, J; Cutler, C; Westervelt, P; Woolfrey, A; Couban, S; Ehringer, G; Johnston, L; Maziarz, R; Pulsipher, MA; Porter, D; Mineishi, S; McCarty, J; Khan, S; Anderlini, P; Bensinger, W; Leitman, S; Rowley, S; Bredeson, C; Carter, S; Horowitz, M; Confer, D
Secondary
N Engl J Med
Volume
367
Start Page
1487
Pagination
1487-1496
Date Published
10/2012
Keywords
Adult; Bone Marrow Diseases/mortality; Bone Marrow Diseases/therapy; Bone Marrow Transplantation/adverse effects; Bone Marrow Transplantation/mortality; Cause of Death; Graft Rejection/epidemiology; Graft vs Host Disease/epidemiology; Histocompatibility
Abstract

BACKGROUND:

Randomized trials have shown that the transplantation of filgrastim-mobilized peripheral-blood stem cells from HLA-identical siblings accelerates engraftment but increases the risks of acute and chronic graft-versus-host disease (GVHD), as compared with the transplantation of bone marrow. Some studies have also shown that peripheral-blood stem cells are associated with a decreased rate of relapse and improved survival among recipients with high-risk leukemia.

METHODS:

We conducted a phase 3, multicenter, randomized trial of transplantation of peripheral-blood stem cells versus bone marrow from unrelated donors to compare 2-year survival probabilities with the use of an intention-to-treat analysis. Between March 2004 and September 2009, we enrolled 551 patients at 48 centers. Patients were randomly assigned in a 1:1 ratio to peripheral-blood stem-cell or bone marrow transplantation, stratified according to transplantation center and disease risk. The median follow-up of surviving patients was 36 months (interquartile range, 30 to 37).

RESULTS:

The overall survival rate at 2 years in the peripheral-blood group was 51% (95% confidence interval [CI], 45 to 57), as compared with 46% (95% CI, 40 to 52) in the bone marrow group (P=0.29), with an absolute difference of 5 percentage points (95% CI, -3 to 14). The overall incidence of graft failure in the peripheral-blood group was 3% (95% CI, 1 to 5), versus 9% (95% CI, 6 to 13) in the bone marrow group (P=0.002). The incidence of chronic GVHD at 2 years in the peripheral-blood group was 53% (95% CI, 45 to 61), as compared with 41% (95% CI, 34 to 48) in the bone marrow group (P=0.01). There were no significant between-group differences in the incidence of acute GVHD or relapse.

CONCLUSIONS:

We did not detect significant survival differences between peripheral-blood stem-cell and bone marrow transplantation from unrelated donors. Exploratory analyses of secondary end points indicated that peripheral-blood stem cells may reduce the risk of graft failure, whereas bone marrow may reduce the risk of chronic GVHD.

Comment in:

Peripheral-blood versus bone marrow stem cells. [N Engl J Med. 2013]

Pursuing the goal of a donor for everyone in need. [N Engl J Med. 2012]

Peripheral-blood versus bone marrow stem cells. [N Engl J Med. 2013]